Allergan to acquire medical aesthetics company for $195m
18-09-2018
Mylan partners to make Botox biosimilar
06-03-2018
Seattle Genetics to acquire biotech company for $614m
02-02-2018
12-02-2018
miodrag ignjatovic / iStockphoto.com
Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Allergan, botox, mergers and acquisitions, Elastagen, clinical-stage, tissue repair, elastin, medical devices